Logo image of TARA

PROTARA THERAPEUTIC INC (TARA) Stock Fundamental Analysis

NASDAQ:TARA - Nasdaq - US74365U1079 - Common Stock

4.73  -0.03 (-0.63%)

Fundamental Rating

3

TARA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. TARA has a great financial health rating, but its profitability evaluates not so good. TARA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TARA had negative earnings in the past year.
TARA had a negative operating cash flow in the past year.
TARA had negative earnings in each of the past 5 years.
In the past 5 years TARA always reported negative operating cash flow.
TARA Yearly Net Income VS EBIT VS OCF VS FCFTARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

The Return On Assets of TARA (-44.69%) is comparable to the rest of the industry.
TARA's Return On Equity of -51.41% is fine compared to the rest of the industry. TARA outperforms 65.13% of its industry peers.
Industry RankSector Rank
ROA -44.69%
ROE -51.41%
ROIC N/A
ROA(3y)-45.59%
ROA(5y)-73.53%
ROE(3y)-50.98%
ROE(5y)-80.84%
ROIC(3y)N/A
ROIC(5y)N/A
TARA Yearly ROA, ROE, ROICTARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

TARA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARA Yearly Profit, Operating, Gross MarginsTARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

TARA has more shares outstanding than it did 1 year ago.
TARA has more shares outstanding than it did 5 years ago.
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TARA Yearly Shares OutstandingTARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
TARA Yearly Total Debt VS Total AssetsTARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 3.88 indicates that TARA is not in any danger for bankruptcy at the moment.
TARA has a better Altman-Z score (3.88) than 78.05% of its industry peers.
There is no outstanding debt for TARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.88
ROIC/WACCN/A
WACCN/A
TARA Yearly LT Debt VS Equity VS FCFTARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.85 indicates that TARA has no problem at all paying its short term obligations.
The Current ratio of TARA (9.85) is better than 80.00% of its industry peers.
TARA has a Quick Ratio of 9.85. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.
TARA has a Quick ratio of 9.85. This is amongst the best in the industry. TARA outperforms 80.18% of its industry peers.
Industry RankSector Rank
Current Ratio 9.85
Quick Ratio 9.85
TARA Yearly Current Assets VS Current LiabilitesTARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

TARA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.18%, which is quite impressive.
EPS 1Y (TTM)33.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TARA will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.93%
EPS Next 2Y3.27%
EPS Next 3Y10.48%
EPS Next 5Y10.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TARA Yearly Revenue VS EstimatesTARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
TARA Yearly EPS VS EstimatesTARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TARA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARA Price Earnings VS Forward Price EarningsTARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARA Per share dataTARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.27%
EPS Next 3Y10.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TARA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTARA THERAPEUTIC INC

NASDAQ:TARA (1/22/2025, 12:47:27 PM)

4.73

-0.03 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners51.55%
Inst Owner Change0%
Ins Owners6.02%
Ins Owner Change-0.89%
Market Cap162.33M
Analysts87.27
Price Target26.93 (469.34%)
Short Float %15.43%
Short Ratio1.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.29%
Min EPS beat(2)5.73%
Max EPS beat(2)44.85%
EPS beat(4)3
Avg EPS beat(4)12.76%
Min EPS beat(4)-3.37%
Max EPS beat(4)44.85%
EPS beat(8)5
Avg EPS beat(8)-5.01%
EPS beat(12)8
Avg EPS beat(12)-0.89%
EPS beat(16)10
Avg EPS beat(16)-0.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)32.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.98
P/tB 1.98
EV/EBITDA N/A
EPS(TTM)-2.82
EYN/A
EPS(NY)-3.33
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0
BVpS2.38
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.69%
ROE -51.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.59%
ROA(5y)-73.53%
ROE(3y)-50.98%
ROE(5y)-80.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.85
Quick Ratio 9.85
Altman-Z 3.88
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)187.07%
Cap/Depr(5y)289.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.53%
EPS Next Y11.93%
EPS Next 2Y3.27%
EPS Next 3Y10.48%
EPS Next 5Y10.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.24%
OCF growth 3YN/A
OCF growth 5YN/A